As the semi-legal peptide sector explodes, driven by a confluence of online trends like "looksmaxing" and the "Make America Healthy Again" movement, more and more suppliers and buyers are turning to cryptocurrency, Chainalysis said Thursday in a new report.
According to the analysis firm, the appetite for off-label peptides — the building blocks of proteins used as a dietary supplement, and across the health, wellness, and fitness spaces — has surged past a $100 million annual run rate. The first quarter of 2026 alone saw a 159% quarter-over-quarter jump to $32 million from $12 million, according to Chainalysis' report.
What started as a niche interest among biohackers has entered the public conversation, primarily driven by the success of GLP-1 peptide drugs like Ozempic and Wegovy, leading to search interest for other solutions that can be used for anything from suppressing appetite to repairing cell damage.
And like the other so-called research chemical "gray market," where derivatives of illicit drugs like fentanyl are sold online often via crypto, the peptide trade is increasingly dominated by Chinese chemical manufacturers, which are often cut off from the traditional banking sector, according to Chainalysis.
"This demand has given rise to ‘gray market’ peptides and a network of overseas suppliers selling raw, unbranded products directly to buyers at a fraction of the pharmacy price," Chainalysis said. "But because traditional banks and credit card processors often prohibit the sale of prescription-grade compounds and unregulated substances, much of this industry operates outside the standard financial system."
"To scale, the gray-market peptide trade adopted cryptocurrency as its backbone," Chainalysis analysts wrote.
According to Chainalysis, the "concentrated cluster of top-tier vendors" that supply much of the peptide market have begun to "exhibit a more professionalized approach to on-chain finance," and often rely on bitcoin and stablecoins.
"When isolating vendors that average $1,000 or more per deposit, the asset mix shifts heavily toward majority stablecoins — a potentially calculated move to insulate massive supply chain orders from the unpredictable price fluctuations of the broader crypto market," Chainalysis wrote.
Safety concerns
The onchain footprint around the emerging peptide sector also revealed that as more buyers are making purchases with crypto, a smaller percentage appears to be also paying to quality test these unregulated substances. According to Chainalysis, before the recent bump in sales, many wallets buying peptides from China frequently also transacted with the independent chemical purity testing company Janoshik, in Czechia.
However, "testing spend crashed by an estimated 88% to just $8 per buyer," even though "Janoshik is actually testing more than ever before," Chainalysis said, due to the sheer rise in the number of buyers.
Chainalysis notes that some organizations accused of selling fentanyl and other drugs appear to be shifting to or expanding into peptides. For instance, Shanghai Sigma Audley, a supplier with suspected connections to transnational drug cartels, had brought in at least $1 million in bitcoin and $3.59 million in stablecoins by selling fentanyl precursors before shifting to peptides, Chainalysis said.
Chainlysis notes that this growing sector often "targets a vulnerable demographic inexperienced with both unregulated pharmaceuticals and cryptocurrency."